Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 11/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 3/20 | 0.41 |
| ▸ | PAK4 | O96013 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16494994 | 0.94 | HTR2A (0.41) | MPONOTUMHTR2AHTR1ASNCA | |
| SCHEMBL16495045 | 0.91 | HTR1A (0.40) | HTR2AHTR1A | |
| SCHEMBL16494871 | 0.90 | HTR1A (0.42) | HTR2AHTR1A | |
| SCHEMBL14839993 | 0.89 | HTR2A (0.42) | SLC6A4HTR2AHTR1AMTNR1AMTNR1B | |
| SCHEMBL16494650 | 0.89 | HTR1A (0.39) | MPOHTR2AHTR1AKMT2A | |
| SCHEMBL16494836 | 0.87 | SNCA (0.42) | HTR2AHTR1AKMT2ASNCA | |
| SCHEMBL14840253 | 0.87 | HTR2A (0.50) | HTR2AKMT2AMTNR1AMTNR1B | |
| SCHEMBL16494972 | 0.87 | ALDH1A1 (0.41) | HTR2AHTR1AKMT2A | |
| SCHEMBL16494684 | 0.87 | HTR1A (0.43) | HTR2AHTR1A | |
| SCHEMBL16494481 | 0.87 | HTR1A (0.47) | MPOHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571867-B1 | NOVEL PYRIMIDINE DERIVATIVES | NOVIGA RES AB (SE) | 2015-11-04 | — | — | EP | claimed |
| US-20130089518-A1 | NOVEL PYRIMIDINE DERIVATIVES | CHEMILIA AB (SE) | 2013-04-11 | — | — | US | claimed |
| EP-2571867-B1 | NOVEL PYRIMIDINE DERIVATIVES | NOVIGA RES AB (SE) | 2015-11-04 | — | — | EP | disclosed |
| US-8927547-B2 | Pyrimidine derivatives | NOVIGA RESEARCH AB (SE) | 2015-01-06 | — | — | US | disclosed |
| US-20130089518-A1 | NOVEL PYRIMIDINE DERIVATIVES | CHEMILIA AB (SE) | 2013-04-11 | — | — | US | disclosed |
| EP-2395001-A1 | Novel pyrimidine derivatives | Chemilia AB (SE) | 2011-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130089518-A1 | NOVEL PYRIMIDINE DERIVATIVES | DPYD, TYMS, TYMP | MPO 4160/4885NOTUM 4344/4885SLC6A4 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.